Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$236.59 USD

236.59
602,304

+7.46 (3.26%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $237.00 +0.41 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Down -21.98% in 4 Weeks, Here's Why Insulet (PODD) Looks Ripe for a Turnaround

by Zacks Equity Research

Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Why Insulet (PODD) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Insulet (PODD) Loses -24.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Indrajit Bandyopadhyay headshot

5 Medical Product Stocks to Buy Amid Industry Recovery

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, BSX, ZBH, PODD and HAE are well-poised to gain from the favorable factors.

Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

What's in Store for Abbott Laboratories (ABT) in Q3 Earnings?

by Zacks Equity Research

Abbott Laboratories' (ABT) third-quarter 2023 results are likely to reflect solid underlying base business organic sales growth.

Down -17.48% in 4 Weeks, Here's Why Insulet (PODD) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Insulet (PODD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Insulet (PODD) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Insulet (PODD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Sanghamitra Saha headshot

Looking for Earnings Beat? 5 Top-Ranked Stocks to Play

by Sanghamitra Saha

These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap NVIDIA (NVDA), Lamb Weston (LW), Insulet (PODD), Asure Software (ASUR) and Palo Alto Networks (PANW).

DexCom (DXCM) Partners With RxFood for Automated Dietary Monitoring

by Zacks Equity Research

DexCom's (DXCM) CGM systems will make dietary assessment through AI-enabled RxFood app, which automatically interprets food images for calorie count in Canada.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Insulet (PODD) on the strength of the Omnipod 5 AID system.

Insulet (PODD) Expands Omnipod 5 Even As Macro Woes Linger

by Zacks Equity Research

Insulet's (PODD) international expansion efforts are aligned with its long-term growth profile.

Zacks Investment Ideas feature highlights: Workday, Energy Transfer and Insulet

by Zacks Equity Research

Workday, Energy Transfer and Insulet are part of the Zacks Investment Ideas article.

Derek Lewis headshot

Insider Buys: 3 CEOs Scooping Up Shares

by Derek Lewis

These 3 CEOs have put their money where their mouths are, recently stepping up and acquiring shares. Given their confidence, should investors follow them into their trades?

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Insulet (PODD) Launches Omnipod 5 AID System in Germany

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 is available in the United States and the United Kingdom.

MDT or PODD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

MDT vs. PODD: Which Stock Is the Better Value Option?

Insulet (PODD) Q2 Earnings Beat, Sales Growth View Raised

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 gains market share in the second quarter within the diabetes technology market as the only FDA-approved fully disposable, pod-based automated insulin delivery system.

Here's What Key Metrics Tell Us About Insulet (PODD) Q2 Earnings

by Zacks Equity Research

The headline numbers for Insulet (PODD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Insulet (PODD) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Insulet (PODD) delivered earnings and revenue surprises of 58.33% and 3.26%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Insulet (PODD) on the strength of the Omnipod 5 AID system.

Minerva Surgical, Inc. (UTRS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Minerva Surgical, Inc. (UTRS) delivered earnings and revenue surprises of 44.44% and 3.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ZBH or PODD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ZBH vs. PODD: Which Stock Is the Better Value Option?